Test Price
2,800 AED✅ Home Collection Available
DNAAF5 Gene Primary Ciliary Dyskinesia Type 18 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- 99.9% Diagnostic Accuracy: Next-Generation Sequencing with ISO 9001:2015-certified protocols ensures definitive mutation identification across the complete DNAAF5 gene coding region.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection: Hospital-grade blood draw by DHA-licensed mobile specialists available daily from 8 AM to 11 PM.
- Post-Test Clinical Guidance: Expert interpretation and genetic counseling by a DHA-licensed Consultant Medical Geneticist to support multidisciplinary care planning.
- Insurance Facilitation: Direct billing verification and pre-approval processing via WhatsApp at +971545488731.
Executive summary: A DHA-licensed molecular genetic test applying next-generation sequencing for definitive diagnosis of primary ciliary dyskinesia type 18, complete with convenient home phlebotomy, expert interpretation, and full data privacy protection under UAE federal law.
Test Overview & Methodology
The DNAAF5 gene test identifies pathogenic variants associated with primary ciliary dyskinesia type 18, a rare autosomal recessive disorder leading to chronic sino-pulmonary infections, neonatal respiratory distress, and possible situs inversus. Our high-throughput next-generation sequencing assay covers the complete DNAAF5 coding region and intron-exon boundaries with greater than 99% analytical sensitivity, delivering a definitive molecular diagnosis that guides multidisciplinary pulmonology, otolaryngology, and fertility management.
Comparative Diagnostic Modalities
| Feature | Our Genetic Test | Sanger Sequencing (Gene-by-Gene) | Ciliary Biopsy (Electron Microscopy) |
|---|---|---|---|
| Method Precision | High-throughput NGS; covers entire gene, greater than 99% sensitivity | Medium; targeted but slower, single gene | Structural assessment only; not genetic confirmation |
| Turnaround Time | 3 to 4 Weeks | 6 to 12 Weeks | 2 to 4 Weeks (invasive sampling) |
| Sample Collection | Blood (whole blood, FTA card) – non-invasive | Blood – non-invasive | Nasal or bronchial brush biopsy – invasive |
| Clinical Utility | Definitive molecular diagnosis, family screening, fertility counseling | Confirmation of single variant only | Functional defect detection, no genetic data |
Pre-Test Information
Provide a detailed clinical history focusing on recurrent respiratory infections, chronic rhinosinusitis, otitis media, bronchiectasis, neonatal respiratory distress, and family history of primary ciliary dyskinesia or situs inversus. A genetic counseling session to draw a pedigree is strongly recommended. No fasting or medication restrictions are required, but list any chronic therapies with the sample.
Physician Insight & Safety Protocols
"I deeply appreciate the emotional weight a family carries when seeking answers for chronic respiratory illness. The DNAAF5 test is a transformative diagnostic tool, yet it must always be correlated with clinical findings, ciliary motility studies, and imaging. A positive result opens the door to tailored multidisciplinary care, from pulmonology to fertility support."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Medication Continuation Notice
Do not discontinue any prescribed medication, including respiratory therapies or prophylactic antibiotics, without explicit instruction from your treating physician. Genetic testing results do not replace ongoing clinical management.
Exclusion Criteria & Urgent Red Flags
Safety Criteria
- Exclusion Criteria: Inability to provide informed consent (minors require legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability); severe coagulopathy or acute anemia – discuss with the mobile phlebotomist before collection.
- Emergency Warnings: If you experience acute shortness of breath, hemoptysis, high fever, or signs of severe infection, proceed immediately to the nearest emergency department. Genetic testing is not intended for acute crisis management.
Patient FAQ & Clinical Guidance
1. What symptoms suggest the need for DNAAF5 genetic testing?
Chronic wet cough, recurrent pneumonia, persistent sinusitis since childhood, neonatal respiratory distress, and situs inversus are clinical red flags that warrant DNAAF5 gene sequencing for primary ciliary dyskinesia type 18. Early molecular diagnosis enables targeted pulmonary hygiene, antibiotic prophylaxis, and fertility planning.
2. How accurate is the DNAAF5 NGS test?
This next-generation sequencing assay delivers greater than 99% analytical sensitivity for pathogenic variants in the DNAAF5 gene, ensuring a definitive molecular diagnosis when interpreted alongside genetic counseling and clinical correlation. Our ISO 9001:2015-certified laboratory maintains stringent quality controls throughout the sequencing pipeline.
3. Will my UAE health insurance cover this genetic test?
Most UAE medical insurance plans reimburse clinically indicated genetic testing for primary ciliary dyskinesia. Our team verifies your policy and processes direct billing via WhatsApp at +971545488731 to minimize out-of-pocket costs. Pre-approval timelines typically range from 2 to 5 working days.
4. How should I prepare for the blood collection appointment?
No fasting is required. Remain well-hydrated and wear comfortable clothing with sleeve access. Bring a valid Emirates ID and any relevant medical records, including previous imaging or pulmonary function test reports. The mobile phlebotomist will confirm your appointment window between 8 AM and 11 PM.
5. What happens after the results are ready?
Our Consultant Medical Geneticist reviews and interprets the report, which is then shared with your referring physician. A telephonic counseling session is scheduled to explain the findings, discuss inheritance patterns, and coordinate specialist referrals for pulmonology, otolaryngology, or reproductive medicine as indicated.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority and complies fully with all applicable federal legislation governing medical diagnostics and patient data protection.
- Data Security: All genetic and personal data are processed and stored in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Informed Consent: Patient consent and clinical safety protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring full transparency in sample collection, testing, and data handling.
- DHA Licensing: Facility License Number 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | DNAAF5 Gene Primary Ciliary Dyskinesia Type 18 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA or FTA card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) – Whole gene coding region and intron-exon boundary analysis |
| ICD-10-CM Code | Q34.8 |
| LOINC Code | 2163-8 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians